| Name | Title | Contact Details |
|---|
Yusef Manufacturing Labs is a Kaysville, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innovation is the leading provider of Pharmacy Intelligence™ and pharmacy automation to the retail, hospital, government, and mail order pharmacy markets. Our PharmASSIST® suite of pharmacy automation and process optimization solutions enable all types of pharmacies to increase operational efficiency, enhance patient safety, and provide a higher quality of patient care. Leveraging our unparalleled Pharmacy Intelligence, you can optimize your pharmacy fulfillment process, develop a proven ROI, and gain complete confidence in your automation decisions before investing. Innovation is a name we carry proudly. It is what we do and in many ways who we are. For three and a half decades we have been bringing new technology to industry. Our approach is simple. We start by understanding the problem and then apply all of our talent, expertise, and resources to create new and inventive ways to solve them. That is Innovation.
Osco Drug is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Manufactures programmable E/P stimulators. The Company manufactures a full line of programmable E/P stimulators to accommodate the needs of cardiologists. The Company also develops, manufactures and markets a diagnostic x-ray and digital radiography sy...
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.